NEC OncoImmunity AS
Empowering cancer immunotherapy with artificial intelligence
TL;DR
What they do: AI-driven biotech focused on neoantigen prediction, personalized cancer vaccines, and B-cell epitope prediction for infectious diseases
Headquarters: Oslo, Norway (Forskningsparken / Oslo Science Park)
Corporate ownership: Subsidiary of NEC Bio B.V. (NEC Corporation group)
Notable backers: Coalition for Epidemic Preparedness Innovations (CEPI) and EASME (grant funder) reported
Team size (reported): ~30 employees
Company Overview
Problem Domain
Cancer immunotherapy and infectious-disease vaccine antigen design
Industry
Biotechnology / Bioinformatics / Immuno-oncology
Funding Track Record
Seed round listed on Crunchbase with CEPI as lead
Grant funding / investor activity noted in 2017–2018 entries
Acquired by NEC Corporation and organized under NEC Bio B.V.
Investor Signal
“CEPI and EASME involvement; acquisition by NEC Corporation”